Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeneDx Holdings Equity Warrant Exp 22 July 2026 WGSWW

Financial Services Healthcare
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing... see more

Recent & Breaking News (NDAQ:WGSWW)

Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate

Business Wire September 16, 2022

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire September 14, 2022

EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SMFR, SMFRW

Business Wire September 13, 2022

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire September 13, 2022

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors

Business Wire September 12, 2022

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire September 9, 2022

SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm

Business Wire September 8, 2022

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire September 8, 2022

Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

GlobeNewswire August 26, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire August 19, 2022

SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm

Business Wire August 18, 2022

Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 15, 2022

Sema4 Announces Changes to its Research & Development Leadership

GlobeNewswire August 15, 2022

Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

GlobeNewswire July 26, 2022

Sema4 Announces Chief Financial Officer Transition Plan

GlobeNewswire June 14, 2022

Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area

GlobeNewswire June 1, 2022

Sema4 to Participate at Two Investor Conferences in June 2022

GlobeNewswire May 26, 2022

Sema4 Reports First Quarter 2022 Financial Results and Business Highlights

GlobeNewswire May 12, 2022

Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 4, 2022

Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

GlobeNewswire May 2, 2022